MgSO4/MR: Effect of Magnesium Sulphate Pretreatment in Pediatric Laparoscopy

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05736744
Collaborator
(none)
58
1
2
20.4
2.8

Study Details

Study Description

Brief Summary

In this study, the investigators will compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective laparoscopic surgeries.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Detailed Description

Deep neuromuscular blockade is known to improve surgical conditions in procedures such as abdominal or pelvic laparoscopic surgery, laparotomy and laryngeal surgery. In addition, deep neuromuscular blockade enables a reduction in pneumoperitoneal pressure, postoperative pain and the incidence of intra-operative and postoperative adverse events. Correspondingly, the use of deep neuromuscular blockade is increasing, and for its maintenance neuromuscular monitoring is essential; the use of neostigmine may also be helpful in achieving a rapid recovery. Magnesium sulphate has gained prominence as an adjuvant drug in multimodal anesthesia and pain medicine. It has several clinical indications, including attenuation of the adrenergic response to tracheal intubation and improved peri-operative analgesia. Magnesium sulphate also enhances the action of non-depolarizing neuromuscular blocking drugs, resulting in potentiation of neuromuscular blockade (NMB).The site of magnesium potentiation of neuromuscular blocking drugs is the motor end plate, where magnesium reduces the release of prejunctional acetylcholine, thereby decreasing the muscle membrane excitability. However, limited data exist concerning the effect of magnesium sulphate on the duration of deep or intense NMB and on the period of no response to nerve stimulation. In this study, the investigators will compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective laparoscopic surgeries.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
58 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
To compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective laparoscopic surgeries.To compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective laparoscopic surgeries.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
The dose of the administered muscle relaxants will be given by an investigator not included in the study.
Primary Purpose:
Treatment
Official Title:
Effect of Magnesium Sulphate Pretreatment on the Onset and Duration of Intense and Deep Neuromuscular Block of Rocuronium Versus Cis-Atracurium in Pediatric Laparoscopic Surgery
Anticipated Study Start Date :
Mar 20, 2023
Anticipated Primary Completion Date :
Feb 20, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Rocuronium/MgSO4

The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia. Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval

Drug: MgSO4
The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
Other Names:
  • Magnesium Sulfate
  • Drug: Rocuronium Bromide
    Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval
    Other Names:
  • Esmeron
  • Active Comparator: Cis-Atracurium/MgSO4

    The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia. Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.

    Drug: MgSO4
    The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
    Other Names:
  • Magnesium Sulfate
  • Drug: Cis-Atracurium
    Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
    Other Names:
  • Nimbex
  • Outcome Measures

    Primary Outcome Measures

    1. The time of no response to nerve stimulation (seconds) [Intraoperative]

      Neuromuscular monitoring will be performed using acceleromyography with the TOF-Watch SX (Organon Ireland Ltd, Dublin, Ireland). Period of no response will be defined as the time period with no response to TOF stimulation (intense and deep NMB).

    Secondary Outcome Measures

    1. Duration of deep NMB (seconds) [Intraoperative]

      The time period from the reappearance of the first response to PTC stimulation to the reappearance of the first response to TOF stimulation.

    2. The duration of moderate NMB (seconds) [Intraoperative.]

      the time period from the reappearance of the first response to PTC stimulation to the reappearance of the first response to TOF stimulation one to three out of four twitches.

    3. NMB onset time (in seconds). [Intraoperative.]

      The time elapsed, in minutes, from the start of the administration of muscle relaxant; cis-atracurium or rocuronium injection to 95% of T1 depression.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age group 2-12 years old

    2. Both genders

    3. Children who will be scheduled to undergo elective laparoscopic surgeries.

    4. Patients with American Society of Anesthesiologist physical status classification of 1 or 2-

    Exclusion Criteria:
    1. Patients who are beyond the selected age group.

    2. Patients on medications that interfered with muscle activity.

    3. Allergy to medications used in this study.

    4. Neuro-muscular diseases.

    5. Renal or hepatic impairment.

    6. Hypermagnesemia (>2.5 mmol) or hypomagnesemia (<1.7 mmol).

    7. Parental refusal to participate in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Pediatric hospital Assiut Assiut Governorate Egypt 715715

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Principal Investigator: Hala Abdel-Ghaffar, MD, Professor of anesthesia and intensive care, faculty of medicine, Assiut university, Assiut, Egypt.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hala Saad Abdel-Ghaffar, Principal Investigator, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05736744
    Other Study ID Numbers:
    • 04-2022-200028
    First Posted:
    Feb 21, 2023
    Last Update Posted:
    Feb 23, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 23, 2023